Analysts Set NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) PT at $42.00

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have earned an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $42.00.

NAMS has been the topic of a number of research analyst reports. Royal Bank Of Canada upped their target price on NewAmsterdam Pharma from $38.00 to $39.00 and gave the stock an “outperform” rating in a report on Thursday, August 7th. Stifel Nicolaus began coverage on NewAmsterdam Pharma in a research note on Tuesday, June 10th. They issued a “buy” rating and a $44.00 price target on the stock. The Goldman Sachs Group began coverage on NewAmsterdam Pharma in a research report on Thursday, July 17th. They set a “neutral” rating and a $27.00 price objective for the company. Cantor Fitzgerald started coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, June 4th. They issued an “overweight” rating and a $42.00 target price on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th.

NewAmsterdam Pharma Trading Down 3.4%

NASDAQ:NAMS opened at $27.52 on Friday. The company has a 50-day moving average price of $24.74 and a 200-day moving average price of $21.09. The stock has a market cap of $3.10 billion, a price-to-earnings ratio of -16.99 and a beta of -0.01. NewAmsterdam Pharma has a 12 month low of $14.06 and a 12 month high of $28.91.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.37. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. The company had revenue of $19.15 million for the quarter, compared to analysts’ expectations of $1.44 million. Equities analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, Director James N. Topper acquired 1,260 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, September 8th. The stock was bought at an average price of $24.99 per share, with a total value of $31,487.40. Following the transaction, the director directly owned 3,027,864 shares in the company, valued at approximately $75,666,321.36. This represents a 0.04% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the business’s stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $24.29, for a total value of $1,214,500.00. Following the completion of the sale, the insider directly owned 119,302 shares in the company, valued at $2,897,845.58. This trade represents a 29.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have bought 2,391 shares of company stock valued at $58,424 and have sold 324,954 shares valued at $7,844,906. Insiders own 20.84% of the company’s stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds have recently bought and sold shares of the company. Quarry LP bought a new stake in NewAmsterdam Pharma during the 1st quarter valued at about $25,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of NewAmsterdam Pharma by 18.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company’s stock valued at $79,000 after buying an additional 662 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of NewAmsterdam Pharma by 130.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company’s stock valued at $123,000 after acquiring an additional 3,390 shares in the last quarter. Avanza Fonder AB purchased a new position in NewAmsterdam Pharma in the 1st quarter worth approximately $127,000. Finally, KLP Kapitalforvaltning AS raised its holdings in NewAmsterdam Pharma by 51.7% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 9,100 shares of the company’s stock worth $165,000 after acquiring an additional 3,100 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.